coronavirus
famili
coronavirida
subfamili
coronavirina
circul
divers
array
mammalian
avian
reservoir
includ
human
bat
pig
cat
dog
rodent
bird
perlman
netland
coronavirus
cov
classifi
four
genera
alpha
beta
gamma
deltacoronaviru
envelop
posit
strand
rna
virus
nm
size
master
de
groot
spike
glycoprotein
radiat
viru
envelop
spheric
particl
respons
characterist
crown
like
appear
coronavirus
fig
four
coronavirus
continu
circul
human
popul
caus
gener
mild
respiratori
diseas
hcov
hcov
alphacoronaviru
hcov
betacoronaviru
hamr
procknow
mcintosh
et
al
fouchier
et
al
van
der
hoek
et
al
woo
et
al
addit
two
zoonot
introduct
coronavirus
human
popul
last
decad
associ
acut
respiratori
distress
syndrom
ard
high
case
fatal
rate
sever
acut
respiratori
syndrom
cov
sar
cov
drosten
et
al
kuiken
et
al
middl
east
respiratori
syndrom
cov
mer
cov
zaki
et
al
sar
cov
caus
first
pandem
centuri
result
c
human
case
case
fatal
rate
sar
epidemiolog
work
group
addit
impact
sar
cov
infect
individu
global
public
health
commun
econom
cost
sar
cov
outbreak
event
estim
billion
brahmbhatt
dutta
although
laboratori
confirm
case
mer
cov
current
report
high
case
fatal
rate
travel
relat
spread
across
multipl
countri
reminisc
sar
cov
pandem
first
human
case
mer
cov
identifi
use
pancoronaviru
revers
transcriptas
polymeras
chain
reaction
rt
pcr
assay
zaki
et
al
mer
cov
specif
quantit
rt
pcr
qrt
pcr
target
region
upstream
e
protein
gene
open
read
frame
rapidli
develop
becom
standard
laboratori
test
diagnosi
mer
cov
corman
et
addit
qrt
pcr
target
rna
depend
rna
polymeras
rdrp
nucleocapsid
n
gene
develop
confirmatori
assay
corman
et
al
world
health
organ
case
definit
mer
cov
focus
patient
suffer
febril
acut
respiratori
diseas
direct
epidemiolog
link
anoth
confirm
case
resid
travel
mer
cov
sourc
countri
confirmatori
laboratori
test
requir
posit
qrt
pcr
least
two
specif
genom
target
singl
posit
target
qrt
pcr
combin
sequenc
second
target
center
diseas
control
prevent
instanc
inadequ
test
neg
test
patient
direct
epidemiolog
link
confirm
mer
cov
case
determin
probabl
case
mer
cov
infect
present
acut
febril
respiratori
ill
primari
case
mer
cov
confin
six
countri
middl
east
saudi
arabia
unit
arab
emir
qatar
jordan
oman
kuwait
travel
relat
case
identifi
tunisia
unit
kingdom
franc
germani
itali
fig
bermingham
et
al
buchholz
et
al
gulland
b
health
protect
agenc
hijawi
et
al
maill
et
al
memish
et
al
puzelli
et
al
limit
secondari
transmiss
occur
mer
cov
introduct
tunisia
franc
unit
kingdom
import
case
mer
cov
infect
germani
itali
lead
subsequ
confirm
infect
buchholz
et
al
b
health
protect
agenc
puzelli
et
al
case
mer
cov
occur
saudi
arabia
larg
within
riyadh
eastern
provinc
center
diseas
control
prevent
januari
confirm
case
mer
cov
fatal
fig
although
case
clinic
sever
contact
surveil
uncov
least
subclin
mild
infect
center
diseas
control
prevent
case
fatal
ratio
mer
cov
much
higher
sar
cov
cfr
sar
epidemiolog
work
group
averag
age
mer
cov
case
year
male
femal
ratio
mer
cov
research
group
case
fatal
ratio
male
femal
ratio
decreas
incid
mer
cov
increas
chang
may
attribut
improv
case
surveil
penttinen
et
al
interestingli
three
quarter
mer
cov
case
occur
patient
comorbid
mer
cov
research
group
common
comorbid
mer
cov
case
diabet
hypertens
obes
cancer
chronic
kidney
heart
lung
diseas
assiri
et
al
comorbid
like
affect
diseas
progress
outcom
strong
correl
chronic
diseas
mer
cov
may
bias
high
rate
risk
factor
popul
affect
countri
kingdom
saudi
arabia
instanc
preval
type
ii
diabet
across
age
preval
obes
al
daghri
et
al
one
quarter
adult
male
smoke
epidemiolog
pathogenesi
studi
necessari
discern
comorbid
impact
suscept
progress
mer
cov
infect
clinic
treatment
mer
cov
patient
center
intens
care
drug
treatment
consist
broad
spectrum
antibiot
often
oseltamivir
drug
target
influenza
viru
albarrak
et
al
zaki
et
al
assiri
et
al
drosten
et
al
gueri
et
al
memish
et
al
omrani
et
al
corticosteroid
use
patient
antifung
administ
necessari
zaki
et
al
assiri
et
drosten
et
al
gueri
et
al
memish
et
omrani
et
al
patient
progress
sever
acut
respiratori
distress
provid
oxygen
therapi
mechan
ventil
extracorpor
membran
oxygen
assiri
et
drosten
et
al
gueri
et
al
health
protect
agenc
memish
et
al
omrani
et
al
five
clinic
describ
saudi
patient
treat
ribavirin
one
given
interferon
ifn
patient
also
infus
intraven
immunoglobulin
assiri
et
al
clinic
case
studi
analys
mer
cov
patient
receiv
treatment
ribavirin
immunoglobulin
publish
rapid
full
genom
sequenc
provid
first
insight
origin
mer
cov
van
boheemen
et
al
cotten
et
phylogenet
analysi
show
close
genet
related
mer
cov
group
c
betacoronavirus
btcov
btcov
detect
insectivor
bat
woo
et
al
although
molecular
clock
analys
suggest
unlik
direct
ancestor
mer
cov
fig
lau
et
al
sinc
mer
cov
identif
close
relat
coronaviru
sequenc
detect
bat
africa
asia
america
eurasia
suggest
widespread
circul
mer
cov
relat
virus
order
chiroptera
annan
et
al
anthoni
et
al
de
benedicti
et
al
ithet
et
al
lelli
et
al
wacharapluesade
et
al
investig
sampl
bat
roost
vicin
first
mer
cov
case
bisha
saudi
arabia
reveal
presenc
nucleotid
rna
fragment
match
rdrp
mer
cov
fece
egyptian
tomb
bat
taphoz
perfor
memish
et
al
unfortun
short
length
mer
like
cov
sequenc
identifi
bat
limit
strength
phylogenet
analys
subsequ
conclus
origin
mer
cov
direct
contact
human
bat
limit
intermedi
speci
often
play
role
transmiss
emerg
virus
bat
human
field
et
al
luo
et
al
mahalingam
et
al
nel
anecdot
evid
mer
cov
patient
contact
farm
anim
report
case
albarrak
et
al
buchholz
et
al
drosten
et
al
mer
cov
research
group
suspicion
potenti
sourc
mer
cov
focus
livestock
common
arabian
peninsula
goat
sheep
dromedari
camel
cow
first
evid
exist
intermedi
anim
reservoir
detect
mer
cov
neutral
antibodi
dromedari
camel
oman
canari
island
spain
reusken
et
subsequ
studi
detect
mer
cov
neutral
antibodi
dromedari
camel
egypt
jordan
saudi
arabia
importantli
camel
serum
collect
unit
arab
emir
hemida
et
al
perera
et
al
reusken
et
meyer
et
al
mer
cov
neutral
antibodi
detect
speci
livestock
test
includ
chicken
goat
sheep
cattl
seroposit
among
camel
pass
everi
locat
even
hemida
et
al
perera
et
al
reusken
et
b
meyer
et
al
high
preval
neutral
antibodi
across
age
grade
suggest
pervas
earli
infect
camel
mer
cov
mer
cov
like
viru
recent
mer
cov
viru
detect
rt
pcr
nose
swab
three
camel
qatar
haagman
et
al
camel
epidemiolog
link
two
human
case
mer
cov
viral
fragment
sequenc
camel
show
high
similar
sequenc
human
case
haagman
et
al
datum
provid
conclus
evid
dromedari
camel
form
part
mer
cov
outbreak
pictur
direct
transmiss
still
unclear
fig
transmiss
could
occur
camel
human
human
camel
concurr
third
sourc
human
camel
haagman
et
al
furthermor
detect
mer
cov
neutral
antibodi
dromedari
camel
region
report
human
case
egypt
canari
island
rais
question
extent
mer
cov
mer
cov
like
viru
circul
africa
arab
peninsula
minor
asia
perera
et
al
reusken
et
movement
camel
africa
arabian
peninsula
common
could
contribut
spread
mer
cov
region
mukasa
mugerwa
perera
et
al
epidemiolog
dynam
describ
basic
reproduct
number
mer
cov
uncertain
measur
number
secondari
case
gener
one
case
diseas
popul
self
limit
within
popul
use
epidemiolog
inform
probabl
case
mer
cov
infect
two
differ
transmiss
scenario
use
estim
mer
cov
breban
et
al
one
scenario
model
larg
number
index
patient
per
cluster
gener
small
transmiss
tree
reflect
possibl
two
epidemiolog
link
case
could
expos
nonhuman
sourc
mer
cov
scenario
yield
yearli
mer
cov
introduct
rate
breban
et
al
second
scenario
use
lower
rate
introduct
higher
human
human
transmiss
predict
yearli
introduct
rate
breban
et
al
larg
scale
analysi
full
genom
sequenc
mer
cov
identifi
multipl
zoonot
introduct
viru
distinct
genom
circul
geograph
space
provid
evid
multipl
zoonot
introduct
transmiss
dynam
agreement
lower
cotten
et
furthermor
comparison
predict
mer
cov
prepandem
sar
cov
suggest
mer
cov
low
pandem
potenti
breban
et
al
anoth
transmiss
model
mer
cov
case
predict
similar
warn
absenc
control
measur
could
rang
allow
self
sustain
transmiss
cauchemez
et
al
base
extrapol
incid
diseas
travel
return
mer
cov
sourc
countri
predict
mani
symptomat
case
mer
cov
may
occur
august
cauchemez
et
al
epidemiolog
studi
necessari
assess
preval
circul
mer
cov
infect
human
popul
grant
bind
viru
host
cell
cellular
receptor
play
import
role
determin
speci
tissu
tropism
coronavirus
thackray
holm
master
tusel
et
al
mer
cov
spike
protein
amino
acid
type
transmembran
glycoprotein
present
trimer
surfac
envelop
viru
translat
spike
protein
cleav
two
domain
subunit
respons
receptor
bind
unit
mediat
membran
fusion
ohnuma
et
al
raj
et
spike
glycoprotein
bind
surfac
enzym
dipeptidyl
peptidas
also
known
type
ii
transmembran
glycoprotein
catalyz
cleavag
n
termin
prolin
contain
dipeptid
aid
glucos
metabol
proteolyt
inactiv
incretin
engel
et
al
hiramatsu
et
al
lambeir
et
al
third
exopeptidas
found
act
receptor
coronavirus
raj
et
al
block
enzymat
activ
affect
mer
cov
suscept
signific
enzym
receptor
coronavirus
thought
lie
widespread
express
endotheli
epitheli
tissu
raj
et
al
rel
conserv
mammalian
speci
allow
mer
cov
bind
speci
divers
bat
human
et
al
raj
et
al
receptor
bind
domain
rbd
mer
cov
region
spike
protein
attach
receptor
map
amino
acid
residu
region
spike
protein
chen
et
al
lu
et
al
mou
et
al
wang
et
al
co
crystal
mer
cov
spike
protein
reveal
interact
beta
propel
blade
beta
strand
mer
cov
rbd
also
known
receptor
bind
motif
rbm
fig
lu
et
al
wang
et
al
rbd
spike
protein
induc
neutral
antibodi
make
import
target
develop
prophylact
therapeut
agnihothram
et
al
du
et
al
b
c
gierer
et
al
song
et
al
infect
experi
human
airway
epitheli
cell
shown
global
transcript
host
respons
earlier
robust
mer
cov
infect
sar
cov
infect
josset
et
al
yet
consist
observ
sar
cov
infect
mer
cov
infect
human
respiratori
cell
lead
pronounc
type
ifn
respons
kopecki
bromberg
et
al
kindler
et
al
zielecki
et
al
type
ifn
play
key
role
viral
immun
pathogen
virus
often
evad
innat
immun
antagonist
protein
disrupt
ifn
reaction
sastr
biron
randal
goodbourn
taylor
mossman
mer
cov
inhibit
type
ifn
demonstr
structur
protein
accessori
protein
encod
orf
orf
orf
yang
et
al
potent
inhibitor
orf
shown
inhibit
type
ifn
activ
block
interact
rna
helicas
sensor
viral
doubl
strand
rna
mechan
distinct
employ
sar
cov
kopecki
bromberg
et
al
niemey
et
al
yang
et
al
effici
mer
cov
replic
also
demonstr
noncili
bronchial
epithelium
alveolar
epitheli
cell
endotheli
cell
macrophag
human
ex
vivo
organ
cultur
chan
et
zhou
et
al
consist
result
obtain
human
respiratori
cell
line
mer
cov
infect
ex
vivo
lead
strong
type
ifn
respons
cultur
chan
et
zhou
et
al
combin
vitro
ex
vivo
data
suggest
mer
cov
activ
interact
evad
innat
immun
recognit
pathway
host
kindler
et
al
ex
vivo
data
support
result
viral
dissemin
patholog
cellular
tropism
establish
rhesu
macaqu
model
de
wit
et
al
gene
express
analysi
experiment
infect
rhesu
macaqu
show
differenti
express
gene
infect
lung
tissu
associ
antivir
immun
inflamm
chemotaxi
includ
il
chemokin
c
x
c
ligand
matrix
metalloproteinas
expect
type
ifn
activ
de
wit
et
al
chemokin
il
strong
recruit
neutrophil
granulocyt
induc
macaqu
perhap
explain
increas
number
neutrophil
record
blood
infect
macaqu
human
patient
zaki
et
al
assiri
et
gueri
et
al
de
wit
et
mathemat
transmiss
model
highlight
two
import
way
mer
cov
control
reduc
rate
mer
cov
introduct
human
popul
break
chain
human
human
transmiss
reduct
rate
mer
cov
introduct
human
popul
requir
comprehens
understand
nonhuman
sourc
mer
cov
spatial
tempor
dynam
mer
cov
circul
sourc
hand
interrupt
human
human
transmiss
cycl
mer
cov
call
understand
paramet
involv
transmiss
viru
shed
stabil
rout
transmiss
although
rout
transmiss
mer
cov
well
understood
spread
mer
cov
peopl
close
contact
set
suggest
direct
contact
fomit
transmiss
rout
like
involv
state
local
mer
cov
infect
lower
respiratori
tract
implic
cough
exud
import
sourc
viru
shed
addit
environment
stabil
mer
cov
provid
inform
potenti
fomit
transmiss
low
temperatur
humid
mer
cov
sar
cov
virion
retain
viabil
smooth
surfac
much
longer
mani
respiratori
virus
includ
influenza
viru
hcov
hcov
sizun
et
al
chan
et
al
van
doremalen
et
al
thu
temperatur
control
set
hospit
may
particular
risk
fomit
transmiss
mer
cov
perform
high
risk
patient
care
procedur
intub
manual
ventil
along
inconsist
use
surgic
mask
associ
nosocomi
transmiss
sar
cov
healthcar
worker
ofner
agostini
et
al
nishiyama
et
al
healthcar
worker
grow
cohort
mer
cov
case
rout
exposur
may
similar
virus
mer
cov
outbreak
character
hospit
base
super
spreader
event
defin
epidemiolog
sar
cov
lipsitch
et
al
infect
sar
cov
viral
load
upper
respiratori
tract
secret
remain
low
first
day
ill
peak
nasopharyng
aspir
day
onset
symptom
peiri
et
al
cheng
et
al
thu
sar
cov
transmiss
could
prevent
gener
popul
basic
public
health
infect
control
measur
isol
patient
neg
pressur
room
activ
surveil
quarantin
contact
provis
educ
protect
equip
healthcar
worker
twu
et
al
svoboda
et
al
estim
serial
interv
mer
cov
infect
largest
cluster
mer
cov
date
case
hospit
set
slightli
shorter
sar
cov
median
vs
day
suggest
transmiss
may
occur
earlier
cours
ill
assiri
et
effect
implement
public
health
measur
current
mer
cov
outbreak
must
integr
knowledg
shed
dynam
exposur
mechan
viru
viabil
antivir
treatment
specif
human
coronavirus
develop
short
live
sar
cov
outbreak
support
treatment
regimen
optim
stockman
et
al
cheng
et
al
commerci
avail
drug
type
ifn
lopinavir
high
concentr
ribavirin
shown
inhibit
cytopath
effect
sar
cov
vitro
studi
synergist
antivir
effect
describ
type
ifn
ribavirin
chen
et
al
tan
et
al
birgit
et
al
drug
use
vari
extent
sar
cov
patient
often
combin
corticosteroid
stockman
et
al
cheng
et
al
ribavirin
structur
analog
guanosin
broad
spectrum
mutagen
effect
virus
despit
frequent
use
sar
cov
patient
ribavirin
shown
effect
patient
advers
effect
hemolyt
anemia
common
stockman
et
al
cheng
et
al
type
ifn
regimen
sar
cov
patient
sometim
use
part
multi
drug
regimen
one
studi
sar
cov
patient
report
rapid
improv
radiograph
lung
patholog
better
oxygen
patient
treat
ifn
loutfi
et
al
stockman
et
al
cheng
et
al
specul
immunopatholog
rather
uncontrol
viral
replic
contribut
lung
deterior
advanc
sar
cov
infect
favor
widespread
use
corticosteroid
treatment
nichol
et
al
peiri
et
al
hui
sung
cheng
et
al
retrospect
analysi
sar
cov
patient
show
benefit
corticosteroid
administr
except
critic
case
analyz
alon
death
relat
variabl
adjust
among
critic
patient
corticosteroid
therapi
significantli
reduc
case
fatal
chen
similarli
corticosteroid
use
mer
cov
patient
sever
diseas
assiri
et
guberina
et
al
memish
et
omrani
et
al
one
previous
healthi
mer
cov
patient
suffer
ard
multidrug
resist
pseudomona
aeruginosa
suspect
concomit
allerg
bronchopulmonari
aspergillosi
improv
rapidli
treat
corticosteroid
prednisolon
guberina
et
al
efficaci
corticosteroid
treatment
mer
cov
patient
ard
report
therapi
use
sar
cov
outbreak
shape
investig
treatment
regimen
mer
cov
mer
cov
show
greater
sensit
sar
cov
antivir
effect
type
type
iii
ifn
vitro
ex
vivo
kindler
et
al
wild
et
al
zielecki
et
al
greater
sensit
could
explain
mechanist
differ
ifn
antagonist
accessori
protein
virus
instanc
mer
cov
lack
homologu
sar
cov
protein
block
activ
effect
ifn
ultim
transcript
activ
downstream
antivir
gene
wild
et
al
comparison
five
differ
ifn
shown
ifn
potent
inhibitor
mer
cov
hart
et
al
although
high
concentr
ribavirin
effect
vitro
one
studi
falzarano
et
anoth
studi
found
inhibitori
effect
ribavirin
dose
translat
current
drug
regiment
human
hart
et
al
ifn
ribavirin
use
combin
mer
cov
howev
effect
concentr
drug
combin
much
lower
individu
drug
addit
effect
decreas
drug
requir
concentr
potenti
achiev
human
falzarano
et
interestingli
ribavirin
significantli
effect
exon
activ
coronavirus
knock
smith
et
al
data
indic
knockout
virus
ribavirin
greater
abil
inhibit
viral
rna
synthesi
inosin
monophosph
dehydrogenas
impdh
enzym
necessari
de
novo
synthesi
guanin
nucleotid
would
explain
rel
high
ribavirin
dose
need
achiev
inhibit
viral
replic
mer
cov
smith
et
al
studi
identifi
compound
inhibit
mer
cov
mycophenol
acid
demonstr
particularli
high
efficaci
mer
cov
chan
et
al
b
c
mycophenol
acid
approv
drug
like
ribavirin
act
inhibit
impdh
typic
use
immunosuppress
tissu
transplant
antivir
activ
attribut
inhibit
viral
rna
replic
diamond
et
al
preliminari
vitro
comparison
suggest
mycophenol
acid
potent
inhibitor
mer
cov
ribavirin
chan
et
falzarano
et
hart
et
al
effect
plasma
drug
level
may
better
achiev
intraven
dose
mycophenol
acid
ribavirin
chan
et
assumpt
vivo
use
drug
effect
vitro
need
made
care
mycophenol
acid
instanc
potent
inhibitor
b
lymphocyt
dendrit
cell
matur
effect
suppress
antigen
present
immunoglobulin
product
villarroel
et
al
well
character
anim
model
advers
immunomodulatori
effect
drug
may
outweigh
reduct
mer
cov
virul
attempt
establish
small
anim
model
mer
cov
syrian
hamster
mice
ferret
unsuccess
coleman
et
al
raj
et
al
b
de
wit
et
howev
experiment
infect
studi
rhesu
macaqu
show
anim
speci
suscept
mer
cov
munster
et
al
rhesu
macaqu
mer
cov
caus
lower
respiratori
tract
infect
reminisc
mild
moder
human
case
de
wit
et
clinic
sign
mer
cov
infect
macaqu
includ
cough
increas
respir
rate
lung
sampl
show
lesion
characterist
mild
mark
pneumonia
munster
et
al
de
wit
et
viru
detect
throughout
respiratori
tract
mediastin
lymph
node
viral
load
higher
earlier
infect
primari
site
viru
replic
type
type
ii
pneumocyt
main
compon
alveolar
architectur
replic
mer
cov
deep
macaqu
lower
respiratori
tract
may
explain
low
potenti
transmiss
mer
cov
despit
renal
failur
human
patient
viru
absent
kidney
tissu
macaqu
de
wit
et
recent
character
mer
cov
rhesu
macaqu
report
transient
fever
infect
monkey
demonstr
mer
cov
specif
antibodi
respons
macaqu
start
day
postinfect
yao
et
al
rhesu
macaqu
model
mer
cov
infect
vivo
model
establish
date
develop
small
anim
model
essenti
conduct
widespread
research
pathogenesi
prophylact
therapeut
countermeasur
antivir
immun
modulatori
compound
shown
effect
mer
cov
vitro
one
treatment
option
examin
vivo
efficaci
combin
ifn
ribavirin
treatment
regimen
test
mer
cov
infect
rhesu
macaqu
falzarano
et
al
dose
design
achiev
serum
concentr
valu
determin
vitro
treat
anim
show
clinic
sign
hematolog
chang
develop
untreat
anim
breath
difficulti
decreas
oxygen
satur
level
increas
neutrophil
count
falzarano
et
al
gross
patholog
lung
treat
anim
normal
untreat
anim
display
visibl
lesion
histopatholog
reveal
mild
sign
bronchointerstiti
pneumonia
treat
anim
abund
alveolar
edema
sever
lesion
seen
untreat
anim
mer
cov
viral
load
lung
sampl
log
lower
treat
anim
compar
untreat
anim
furthermor
lung
specif
host
respons
occur
untreat
macaqu
treat
anim
increas
level
cytokin
chemokin
il
ifn
mcp
reduc
express
inflammatori
gene
observ
lung
treat
anim
falzarano
et
al
signific
improv
clinic
score
treat
anim
despit
rel
similar
viral
load
group
suggest
immunopatholog
may
factor
sever
mer
cov
infect
howev
rhesu
macaqu
model
recapitul
mild
moder
diseas
human
effect
drug
mer
cov
induc
ard
unclear
time
also
critic
efficaci
treatment
patient
begin
treatment
quit
ill
wherea
drug
regimen
macaqu
began
h
postinocul
translat
drug
regimen
laboratori
clinic
must
address
discrep
year
sinc
sar
cov
outbreak
attempt
made
prepar
reemerg
establish
vaccin
advent
mer
cov
heighten
need
effect
coronaviru
vaccin
inactiv
virus
live
attenu
virus
dna
vaccin
viru
like
particl
viral
vector
base
vaccin
shown
produc
neutral
antibodi
sar
cov
chen
et
al
zhao
et
al
graham
et
al
tseng
et
al
unfortun
sar
cov
caus
pulmonari
immunopatholog
upon
challeng
vaccin
anim
model
presum
induc
immun
respons
skew
toward
helper
cell
respons
tseng
et
al
inactiv
viru
vaccin
particularli
prone
induc
type
relat
hypersensit
immunopatholog
upon
challeng
observ
sar
cov
base
viral
vector
vaccin
deme
et
al
viru
like
particl
vaccin
tseng
et
al
dna
vaccin
zhao
et
al
investig
antigen
serolog
relationship
mer
cov
coronavirus
confirm
neutral
antibodi
target
spike
protein
mer
cov
specif
mer
cov
n
protein
induc
antibodi
cross
reactiv
within
coronaviru
subgroup
agnihothram
et
al
spike
protein
especi
rbd
consid
key
compon
coronaviru
vaccin
design
du
et
al
c
replic
defect
vaccinia
viru
base
vaccin
express
full
length
spike
protein
mer
cov
shown
produc
high
level
neutral
antibodi
mice
viru
challeng
appli
mous
model
song
et
al
vaccin
recombin
protein
contain
truncat
rbd
spike
protein
amino
acid
fc
human
igg
also
induc
high
titer
neutral
antibodi
truncat
rbd
elicit
higher
level
neutral
antibodi
vaccin
recombin
protein
contain
larger
fragment
spike
protein
amino
acid
author
suggest
non
neutral
epitop
within
region
polypeptid
may
compet
neutral
epitop
destabil
format
rbd
du
et
al
maxim
protect
neutral
antibodi
across
mer
cov
strain
natur
variat
mer
cov
spike
protein
need
character
consid
design
vaccin
graham
et
al
live
attenu
virus
anoth
approach
mer
cov
vaccin
develop
mer
cov
mutant
lack
structur
e
protein
shown
replic
compet
propag
defect
et
al
develop
safe
effect
mer
cov
vaccin
must
potenti
overcom
challeng
aros
sar
cov
vivo
test
vaccin
perform
date
remain
therefor
unclear
whether
challeng
mer
cov
would
illicit
pulmonari
immunopatholog
upon
challeng
creativ
approach
use
adjuv
promot
cell
respons
need
pursu
potenti
vaccin
must
rigor
evalu
anim
model
graham
et
al
despit
mani
advanc
understand
mer
cov
outbreak
major
question
remain
epidemiolog
mer
cov
still
poorli
understood
although
dromedari
camel
implic
like
intermedi
reservoir
detail
genet
variat
mer
cov
virus
circul
camel
human
necessari
identifi
camel
definit
sourc
human
mer
cov
infect
widespread
distribut
dromedari
camel
across
africa
arab
peninsula
south
west
asia
highlight
potenti
facilit
outbreak
spread
fig
inform
spatial
tempor
pattern
mer
cov
circul
speci
need
zoonot
introduct
continu
play
role
epidemiolog
mer
cov
human
cotten
et
al
elucid
mechan
zoonot
transmiss
essenti
intervent
strategi
focu
control
event
clinic
understand
mer
cov
infect
base
limit
report
albarrak
et
al
bermingham
et
al
assiri
et
al
drosten
et
al
gueri
et
al
memish
et
al
omrani
et
al
particular
interest
effect
comorbid
mer
cov
pathogenesi
patient
outcom
preliminari
evid
show
direct
relat
underli
comorbid
diseas
sever
assiri
et
observ
primari
case
sever
secondari
case
even
control
underli
condit
might
suggest
primari
case
expos
higher
viru
dose
secondari
case
mer
cov
research
group
could
also
indic
mer
cov
readili
transmiss
intermedi
reservoir
human
human
human
milder
mer
cov
case
would
less
like
effici
transmit
mer
cov
human
human
transmiss
could
increas
mer
cov
becom
better
adapt
human
prolong
mer
cov
replic
immun
compromis
patient
could
increas
opportun
viru
acquir
mutat
enabl
effici
transmiss
develop
test
mer
cov
therapeut
current
hinder
absenc
small
anim
model
addit
phase
clinic
trial
need
conduct
experiment
vaccin
treatment
option
avail
human
accordingli
research
focus
alreadi
approv
drug
treatment
mer
cov
result
faster
implement
wider
avail
therapeut
clinic
increas
emerg
infecti
diseas
event
last
decad
made
appar
complet
understand
ecolog
biolog
polit
economi
infecti
diseas
emerg
necessari
global
climat
chang
habitat
alter
wildlif
encroach
like
contribut
novel
interact
pathogen
host
adequ
prepar
futur
infecti
diseas
outbreak
requir
strong
intern
relationship
research
monitor
surveil
public
health
respons
face
emerg
sar
cov
avian
influenza
develop
intern
health
regul
coordin
global
respons
emerg
health
threat
structur
mer
cov
respons
accord
regul
form
emerg
committe
mer
cov
creat
case
definit
infect
provid
frequent
updat
mer
cov
outbreak
ihr
global
alert
respons
function
program
monitor
emerg
diseas
prome
mail
commun
first
report
mer
cov
infect
human
also
continu
provid
global
health
research
commun
updat
epidemiolog
report
scientif
find
capac
build
knowledg
transfer
train
futur
gener
scientist
key
factor
form
multidisciplinari
prepared
futur
infecti
diseas
outbreak
regard
special
attent
given
prevent
control
emerg
infecti
diseas
develop
world
origin
major
infecti
diseas
outbreak
